Goldman Sachs upgraded Marsh McLennan (MMC) to Neutral from Sell with a price target of $195, down from $200. In light of the introduction of Marsh McLennan’s new Thrive program, the potential for modest organic growth tailwinds in the United States and Canada from the inclusion of the McGriff acquisition in organic growth, and the firm’s 2026 organic growth estimate now being below the Economics team’s expectations for U.S. nominal GDP growth, the analyst expects that its estimates and the stock’s valuation are likely close to bottoming.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMC:
- BMO cuts Marsh McLennan price target, says shares ‘potentially not inexpensive’
- Marsh McLennan price target lowered to $195 from $215 at Morgan Stanley
- Marsh McLennan price target lowered to $237 from $243 at Evercore ISI
- Marsh & McLennan Companies: Hold Rating Reaffirmed Amid Operational Challenges and Macroeconomic Uncertainties
- Marsh McLennan price target lowered to $212 from $222 at Wells Fargo